With TASCENSO ODT it’s time for convenience.

TASCENSO ODT® is a multiple sclerosis (MS) treatment with patients’ needs in mind. It is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet (ODT) formulation,1 accompanied by Cycle Vita™, our dedicated support platform.

It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.1

See the data
Enroll your patients now

NOT ACTUAL PATIENT

Tascenso Care Icon

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated hub support program, which delivers individualized product support* at every step. Including:

  • TASCENSO Time Program (baseline assessments and first dose observation)
  • Financial assistance (including co-pay)
  • Bridge Program
  • Medication Adherence Support
Find out more
Tascenso Dissolve Icon

Product

TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet formulation.1

  • Unique orally disintegrating tablet for MS treatment
  • Same proven fingolimod
  • Same efficacy & safety as Gilenya®
  • Not a generic²
  • Not substitutable at the pharmacy level²
  • Dissolves on the tongue in seconds
  • Once daily, with or without food, with or without water
  • Available as 0.25 mg and 0.5 mg orally disintegrating tablets
  • Every batch tested and verified
Find out more

References

1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.

2. FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed April 25th 2023. Available: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

Gilenya® is a registered trademark of Novartis AG.